Global Market Study on Single-Domain Antibody Platforms: Rising Adoption in Antiviral Drug Development Surging Market Growth


Single Domain Antibody Platforms  Market
  • Published On : Nov-2020 |
  • Pages : 233 Pages |
  • Format : Single Domain Antibody Platforms  Market Single Domain Antibody Platforms  Market Single Domain Antibody Platforms  Market Single Domain Antibody Platforms  Market

As per the International Federation of Pharmaceutical Manufacturers & Associations, out of the total expenditure on drug discovery, 25% is spent on preclinical testing. Implementation of single-domain antibodies for drug discovery saves money and shortens the very lengthy process, contributing to higher demand in the single-domain antibody platforms market. For instance, in 2017, Sanofi (Ablynx N.V.) announced that it had completed the preparation of a pre-clinical package for a novel Nanobody® (ALX-1141) in osteoarthritis

Single-domain antibodies are highly successful against and potent inhibitors of viral infections, including hepatitis C virus (HCV), influenza viruses, HIV-1, and enteric viruses. According to TI Pharma and the European Trade Association, research investment for drug discovery has grown 5.2 times in the U.S. and 3.3 in Europe from the past two decades. With advancements in pharmaceutical therapies such as personalized therapies and increasing medical research to discover novel innovative drugs, demand for advanced methods of preclinical testing has witnessed an upsurge. Such factors will result in rapid expansion of the single-domain antibody platforms market size, which is projected to be 3X over the next ten years.

Single-Domain Antibody Platforms Market Trends

Approval & Launch of Novel Immunotherapies with Help of Single-Domain Antibodies: Leading industry players are focusing on development and launch of novel immunotherapies with the help of single-domain antibodies to treat various types of cancers and infectious diseases. This accelerated availability of single-domain antibodies for Immunotherapeutics is expected to boost the growth of the single-domain antibody platforms market over the coming years. For industry players, ROI is high for cancer therapeutics, owing to right of market exclusivity, high selling prices, and government incentives for such novel treatment options.

  • In April 2019, there was a collaboration between REMD Biotherapeutics Inc. & GenScript Biotech for development of several bispecific antibodies. According to the agreement, GenScript will allow REMD to use its SMAB (Single-Domain Antibody fused to Monoclonal Ab) platform, a bispecific antibody platform, to develop novel tumor immunotherapy drugs.
  • In July 2016, ProSci Incorporated announced the release of multiple single-domain antibodies against the human programmed death ligand 1 (PD-L1).

Focus on Offering Single-Domain Antibody Platform Services in Developing Regions: Although the single-domain antibody platform services market has several leading players as well as multiple domestic companies, there are a limited number of companies with complete focus on being a provider of single-domain antibody platform services. Different manufacturers have different specializations and service offerings, with most large companies combining research products, biologics, recombinant proteins, and customized antibody products.

Manufacturers having focus on single-domain antibody platforms ensure better quality of service and an established distribution network that can ensure product availability around the globe. R&D spending on life sciences is among the largest, and is expected to grow at a stable rate over the next several years. Moreover, focus on emerging economies and increasing R&D investments will boost the growth of the single-domain antibody platforms market. Developing economies such as China, India, and Brazil have ample professional manpower and skilled labour at affordable costs, thereby increasing the scope for outsourcing biotech projects.

Research Collaboration, Product Licensing, Acquisition, and Expansion in Emerging Economies: Product or technology licensing and acquisition offers great opportunities to strengthen market positioning. In addition, these strategies provide significant growth opportunities in terms of early market entry and product/technology differentiation.

Increasing investments in the healthcare sector in developing economies are anticipated to boost demand for single-domain antibody therapeutics in developing regions. Higher cancer patient pool and increasing per capita income can provide significant market opportunities in the future.

  • For instance, in April 2019, GenScript allowed REMD Biotherapeutics Inc to use its single-domain antibody platform, to produce bispecific antibodies during drugs development for novel tumor immunotherapy.

Specialized developers are gaining significant traction in the single-domain antibody platforms market. Leading industry players collaborate actively with innovative startups and academic research centers. These collaborations provide long-term, high-ROI opportunities.

  • For instance, in March 2017, Ablynx N.V. and Merck KGaA entered into a collaboration to check the efficacy of the bispecific anti-IL-17A/F Nanobody® (M1095; ALX-0761) in patients with chronic plaque psoriasis.

Regional Outlook of Single-Domain Antibody Platforms Market

North America holds more than 35% the single-domain antibody platforms market share, due to increased adoption of biological services by researchers for their projects to reduce time and errors. Moreover, single-domain antibodies are effective against infectious disease. Europe holds the second-largest share in the single-domain antibody platforms market, due to awareness about single-domain antibodies in immune therapy in the region. Asia Pacific and the Middle East & Africa are expected to hold lucrative market shares. Increased R&D investments, collaborative research, and government initiatives are expected to further support the growth of the single-domain antibody platforms market in these regions.

COVID-19 Impact on Single-Domain Antibody Platforms Market

The global outbreak of COVID-19 has had a positive impact on the single-domain antibody platforms market. There is increasing need for antiviral antibodies in the development of new drugs and treatment options for the new coronavirus. Single-domain antibodies have confirmed their potential in treating coronavirus to some extent. However, in the 1st half of 2020, the pandemic created a short term-decline in the manufacturing and sales of single-domain antibodies, as a result of shutdowns and less production at manufacturing facilities.

Analysts’ Viewpoint

An analysis of the single-domain antibody platforms market has brought our analysts to a conclusion that, the market is growing at a remarkable pace. Currently, the bispecific single-domain antibody is the most lucrative segment for leading service providers, and, as such, this segment dominates the global single-domain antibody platforms market by platform type in term of growth. Currently North America holds more than half of the revenue share due to increasing drug development activities in the region. Developing countries such as India, Brazil, China, and Thailand are expected to offer lucrative opportunities for players in the single-domain antibody platforms market, owing to increasing awareness and initiatives by local governments for research & development.

Single-Domain Antibody Platforms Market - Scope of Report

A latest publication by Persistence Market Research (PMR) on the global single-domain antibody platforms market evaluates the opportunities and current market landscape, and provides detailed analysis and updates about corresponding sections affecting the global single-domain antibody platforms market. The study offers detailed insights on key market dynamics, which include the drivers, restraints, trends, and opportunities in the single-domain antibody platforms market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2020-2030.

Important indicators for successful growth of the single-domain antibody platforms market are presented in this comprehensive report, which include Year-on-Year (Y-o-Y) growth analysis of the market and compounded annual growth rate (CAGR). This research study can support readers to know the demand for single-domain antibody platforms and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in the single-domain antibody platforms market space, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the single-domain antibody platforms market. The insights and wisdom presented in this PMR study can be leveraged by shareholders in the single-domain antibody platforms market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.

Market statistics as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the single-domain antibody platforms market are also included in the current study. Depending on potential developments in the single-domain antibody platforms market, substantive insights are also encountered in this report. Additionally, by virtue of the data submitted in this report, minor companies and new entrants in the single-domain antibody platforms industry can be aided in making suitable company choices to achieve traction in the market.

Key Segments of Single-Domain Antibody Platforms Market

PMR’s study on the single-domain antibody platforms market offers information divided into five important segments — platform type, animal source, application, end user, and region. This report offers comprehensive data and information about the important market dynamics, and growth parameters associated with these categories.

Platform Type  

  • Multi-specific Single Domain Antibody
  • Bispecific Single Domain Antibody
  • Multivalent Single Domain Antibody
  • Mono-specific Single Domain Antibody

Animal Source

  • Camelids
    • Camels
    • Llama
    • Alpacas
  • Sharks

Application

  • Diagnostic Laboratories
  • Therapeutic Development
  • Research & Development Activities

End User

  • Diagnostic Laboratories
  • Clinical Laboratories
  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa (MEA)

Key Questions Answered in PMR’s Single-Domain Antibody Platforms Market Report

  • Which regions will continue to remain the most profitable regional markets for single-domain antibody platforms market players?
  • Which factors will induce a change in the demand for single-domain antibody platforms during the assessment period?
  • How will changing trends impact the single-domain antibody platforms market?
  • How can market players capture the low-hanging opportunities in the single-domain antibody platforms market in developed regions?
  • What are the winning strategies of stakeholders in the single-domain antibody platforms market to upscale their position in this landscape?
  • What are the restraints that investors need to be aware of and might tackle while investing in the single-domain antibody platforms market?
  • What are the developmental trends in single-domain antibody platform sectors that will impact the market?
  • How can businesses in the single-domain antibody platforms market avail growth the opportunities in developed and emerging sectors?

Single-Domain Antibody Platforms Market: Research Methodology

In PMR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the single-domain antibody platforms market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the single-domain antibody platforms market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the single-domain antibody platforms market, and makes PMR’s projections on the growth prospects of the market more accurate and reliable.

Companies covered in Single Domain Antibody Platforms Market Report

  • Creative BioLabs A
  • Synbio Technologies
  • ProSci Incorporated
  • BioCat GmbH
  • Antibody Design Labs
  • GenScript
  • Oak BioSciences, Inc.
  • Rockland Immunochemicals, Inc
  • Hybrigenics Services
  • NeoClone Biotechnology International LLC
  • Kaneka Eurogentec S.A
  • ProteoGenix

Single Domain Antibody Platforms Market

Back To Top